Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ionis Pharmaceuticals
(NQ:
IONS
)
41.84
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
41.84
Bid (Size)
41.70 (2)
Ask (Size)
52.51 (1)
Prev. Close
41.84
Today's Range
41.84 - 41.84
52wk Range
34.32 - 54.44
Shares Outstanding
141,797,854
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Latest Analyst Ratings For Ionis Pharmaceuticals
April 09, 2024
Via
Benzinga
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
March 13, 2024
Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with...
Via
Benzinga
Performance
YTD
-20.86%
-20.86%
1 Month
-4.71%
-4.71%
3 Month
-19.24%
-19.24%
6 Month
-9.59%
-9.59%
1 Year
+17.13%
+17.13%
More News
Read More
Are These 5 Undervalued Stocks Ready to Break Out?
March 08, 2024
Via
MarketBeat
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024
From
Biogen Inc.
Via
GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
February 22, 2024
Via
Benzinga
Earnings Scheduled For February 21, 2024
February 21, 2024
Via
Benzinga
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
February 01, 2024
Via
Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
Via
Benzinga
Exposures
Product Safety
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
January 22, 2024
Via
Benzinga
Exposures
Product Safety
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
January 18, 2024
Via
Benzinga
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
January 08, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Where Ionis Pharmaceuticals Stands With Analysts
November 17, 2023
Via
Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
October 23, 2023
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Via
Investor's Business Daily
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
January 04, 2024
Via
Benzinga
Topics
ETFs
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies
December 27, 2023
Via
InvestorPlace
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
December 22, 2023
Via
Benzinga
Exposures
Product Safety
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment
December 22, 2023
Via
Benzinga
Exposures
Product Safety
Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach
December 19, 2023
Via
Benzinga
Based on good technical signals, IONIS PHARMACEUTICALS INC is potentially setting up for a breakout.
December 19, 2023
Via
Chartmill
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
November 16, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Technical Insights for IONIS PHARMACEUTICALS INC (NASDAQ:IONS): Is a Breakout Imminent?
November 10, 2023
Via
Chartmill
Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat
November 02, 2023
Via
Benzinga
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?
October 17, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.